Our primary objective is to correlate the measured heart rates between ECG measurements and the Elfi-Tech dynamic light scattering sensor.
ID
Source
Brief title
Condition
- Other condition
- Body temperature conditions
- Hepatobiliary neoplasms malignant and unspecified
Synonym
Health condition
prematuriteit
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study endpoint is the correlation of the detection of heart rate in
beats per minute between ECG and the Elfi-Tech DLS sensor.
Secondary outcome
The correlation between flow measured with the Elfi-Tech DLS and Pulse Index
(PI) from the pulse oximeter
Peak detection and beat to beat analysis for the detection of measurement
errors and signal disturbances.
Determination of optimal measurement site.
Assessment of measurement quality in patient groups with impaired peripheral
perfusion; sepsis and therapeutic hypothermia.
Heart rate variability measurements with ECG, pulse oximetry and the Elfi-Tech
DLS sensor and their correlation.
Background summary
One of the most important vital parameters that are measured in neonates is
heart rate. This is most commonly detected using electrocardiography (ECG).
Prematurely born infants in particular are known for frequent episodes of
bradycardia (slow heart rate) that require adequate detection because they
indicate low cardiac output. To date electrocardiography is the gold standard
for non-invasive heart rate detection. Pulse oximetry is also common clinical
practice for non-invasive heart rate monitoring, as it provides the blood
oxygen saturation as well. Both ECG and pulse oximetry have a very small signal
amplitude in neonates, which makes it difficult to detect and even harder to
properly quantify the signal. Another major issue is signal distortion by
movement of the neonate and in the case of ECG also electromagnetic
interference. An important remark concerning the measurement of vital signs in
(premature) neonates is their very small size, allowing only a limited number
of sensors for patient monitoring. The company Elfi-Tech has recently developed
a new dynamic light scattering sensor which is able to measure heart rate
through the assessment of skin blood flow with a single sensor. This new
measuring technique is less susceptible to movements of the neonate or to
electromagnetic interference.
Study objective
Our primary objective is to correlate the measured heart rates between ECG
measurements and the Elfi-Tech dynamic light scattering sensor.
Study design
This study is a prospective observational study. After informed consent is
obtained we will measure for 75 minutes with the Elfi-Tech DLS sensor on 5
different sites. This measurement is compared to heart rate measurements
obtained by ECG monitoring at the same time. Also a secondary pulse oximeter
will be attached
Study burden and risks
We will perform non-invasive measurements for the duration of 75 minutes, the
burden associated with participation is therefore minimal.
When the sensor is placed it does not come into direct contact with the skin,
but is attached to a certified biocompatible double-sided adhesive which
functions as a barrier. These double-sided adhesives have often been used in
neonatal studies and are known to have no consequences for the premature skin.
This DLS sensor contains a divergent class 1 laser source that is safe from any
distance. This means that even when directly viewing this laser with the naked
eye the maximum permissible exposure cannot be exceeded, making it harmless to
the eye. However, considering the frailty of the neonates in which this study
is performed the sensors will be handled with caution and exposing the eyes of
the patients to the laser will be avoided at all times. The rationale is that
even though a class 1 is deemed safe in the general population, the neonatal
retina and the premature retina in particular, is more sensitive. In addition,
information on the consequences of exposing the eye of a neonate to a class 1
laser is lacking.
Wytemaweg 80
Rotterdam 3015 CN
NL
Wytemaweg 80
Rotterdam 3015 CN
NL
Listed location countries
Age
Inclusion criteria
Aged 26 weeks of gestation or older.
Monitored by electrocardiogram in the Neonatal Intensive Care Unit of the Sophia Children*s Hospital.
Written informed consent.
Exclusion criteria
Absence of written informed consent
A gestational age of < 26 weeks
Skin disorder (including frailty of the skin) for which the double sided skin adhesive is contraindicated.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL59350.078.16 |